Bnp Paribas Arbitrage Sa Has Raised Its Ambev Sa (ABEV) Stake by $6.51 Billion as Shares Rose

Ambev S.A. (NYSE:ABEV) Logo

Bnp Paribas Arbitrage Sa increased its stake in Ambev Sa (ABEV) by 6.06% based on its latest 2018Q4 regulatory filing with the SEC. Bnp Paribas Arbitrage Sa bought 1.66 million shares as the company’s stock rose 3.77% with the market. The institutional investor held 29.04M shares of the beverages (production and distribution) company at the end of 2018Q4, valued at $113.84B, up from 27.38M at the end of the previous reported quarter. Bnp Paribas Arbitrage Sa who had been investing in Ambev Sa for a number of months, seems to be bullish on the $64.00B market cap company. The stock decreased 2.17% or $0.09 during the last trading session, reaching $4.05. About 35.27 million shares traded or 27.09% up from the average. Ambev S.A. (NYSE:ABEV) has declined 34.33% since May 17, 2018 and is downtrending. It has underperformed by 38.70% the S&P500.

Bnp Paribas Arbitrage Sa, which manages about $42331.08B US Long portfolio, decreased its stake in Inovio Pharmaceuticals Inc (NASDAQ:INO) by 3,029 shares to 31 shares, valued at $124,000 in 2018Q4, according to the filing. It also reduced its holding in Gnc Holdings Inc (Put) (NYSE:GNC) by 120 shares in the quarter, leaving it with 375 shares, and cut its stake in Mobile Telesystems Pjsc (NYSE:MBT).

More important recent Ambev S.A. (NYSE:ABEV) news were published by: which released: “Ambev Shares May Have Bottomed Out At $4.00 – Seeking Alpha” on February 05, 2019, also published article titled: “Mixed Results For Ambev – Seeking Alpha”, published: “Ambev S.A. (ABEV) CEO Bernardo Paiva on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” on May 07, 2019. More interesting news about Ambev S.A. (NYSE:ABEV) was released by: and their article: “Ambev S.A. 2019 Q1 – Results – Earnings Call Slides – Seeking Alpha” with publication date: May 07, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.